Tags : Cologuard

Exact Sciences and Pfizer Announce Extension and Amendment of their

Shots: Pfizer will continue to provide sales and marketing support and health system support for Cologuard through the end of 2022 and 2021, respectively. Exact Sciences will compensate Pfizer based on the amount of services provided, along with additional fixed and performance-related fees set forth in the agreement Cologuard was approved by US FDA in […]Read More

Exact Sciences and Mayo Clinic Initiate Voyage Study Evaluating the

Shots: Exact & Mayo has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening, incidence, and mortality rates. The Voyage study will provide additional, real-world evidence demonstrating the clinical impact of Cologuard & position it as SoC in colorectal cancer screening The Voyage study is a prospective, […]Read More

Pfizer to co-promote Exact Sciences’ Cologuard

Shots: Pfizer signed a Co-promotion agreement for Exact Sciences Cologuard,first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer(CRC)  Pfizer will co-promote Cologuard with Exact from Q4’18, also share total profits and marketing costs equally, Exact will take care of all manufacturing and laboratory operations for Cologuard Cologuard is a DNA screening test […]Read More